# Arcus Biosciences, Inc. (RCUS) FY2026 Q2 P&L / Income Statement

- Company: Arcus Biosciences, Inc. (RCUS)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001724521-26-000044
- Page: https://plicit.ai/financials/rcus/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/rcus-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 41,000,000 US dollars
- **Total operating expenses**: 137,000,000 US dollars
- **Loss from operations**: negative 96,000,000 US dollars
- **Total non-operating income, net**: 5,000,000 US dollars
- **Income (loss) before income taxes**: negative 91,000,000 US dollars
- **Income tax expense**: 0 US dollars
- **Net income (loss)**: negative 91,000,000 US dollars
- **License and development services**: 16,000,000 US dollars
- **Other collaboration**: 25,000,000 US dollars
- **Total operating expenses**: 137,000,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.